Dr Lalchandani Labs Limited returned to profitability in the financial year ended March 31, 2026, reporting a net profit of ₹6.35 lakh compared to a loss of ₹13.15 lakh in the previous year. The turnaround was driven by a one-time settlement gain of ₹61.08 lakh booked under exceptional items, which offset operational challenges. Revenue from operations for the year stood at ₹418.58 lakh, a slight decline from ₹445.38 lakh in FY25, while total expenses decreased to ₹418.04 lakh from ₹470.05 lakh in the prior year.

The Board of Directors, at its meeting held on June 03, 2026, approved the audited standalone financial results for the year and half-year ended March 31, 2026. The meeting also saw the appointment of M/s. Brickwork Ratings India Private Limited as the Monitoring Agency for the utilization of Rights Issue Proceeds, replacing M/s. Infomerics Valuation and Ratings Limited. The trading window for the company's securities will remain closed until 48 hours after the declaration of the results, in accordance with SEBI regulations.

The financial statements were subject to a qualified opinion from the statutory auditor, ATN & CO. The qualifications highlighted that the company's accounts with lenders have been classified as Non-Performing Assets (NPA), and no working capital limit was sanctioned or renewed during the year. Additionally, the company has defaulted on the repayment of term loans and unsecured loans despite having significant cash and cash equivalents. The auditors also noted that statutory dues for PF and ESIC have not been paid for the current and previous financial years, and provisions for gratuity and leave encashment liabilities have not been made in compliance with Accounting Standard-15.

Financial Performance for FY26

The company stated that the impact of the audit qualifications has been adjusted and accounted for in the audited financials to the extent quantifiable. The Board also reviewed the unaudited results for the half-year ended September 30, 2025, which showed a net loss of ₹2.65 lakh.

Dr Lalchandani Labs Limited opened a new strategic centre at Vardhman Star City Mall in Dwarka, New Delhi, on May 28, 2026, to expand its geographic presence. The facility targets the large Government employee population residing in Dwarka and surrounding areas, regions where the company has historically received limited business. This expansion is expected to generate business of approximately Rs 1 Crore per annum, contributing to overall growth and market penetration.

The new centre aims to enhance customer outreach, improve accessibility, and deliver efficient services to clients in the region. The company believes the strategic location will significantly strengthen brand visibility and business development initiatives in West Delhi. Arjan Lalchandani, Managing Director, stated that the opening is an important step towards expanding the company's footprint in high-potential markets.

Business Expectations

The company has outlined specific financial targets for the new facility:

About Dr Lalchandani Labs Limited

Dr Lalchandani Labs Ltd is a Delhi-based integrated diagnostic healthcare company engaged in providing pathology and diagnostic testing services. The company operates through NABL Accredited diagnostic laboratories, collection centres, and institutional partnerships. It offers a comprehensive portfolio of diagnostic services including biochemistry, hematology, immunology, microbiology, molecular diagnostics, hormone assays, and preventive health packages, supported by modern diagnostic infrastructure.